FDA Form 0356V is required for all paper submissions supporting new animal drug applications, abbreviated new animal drug applications, and applications for conditional approval to the FDA’s Center for Veterinary Medicine. Under 21 CFR 514.1 and sections 512(b)(1), 512(n)(1), and 571(a)(2) of the Federal Food, Drug, and Cosmetic Act, this form serves as the certification and cover document that validates your submission meets federal regulatory standards. Without proper Form 0356V completion, your application faces immediate administrative delays that can push back approval timelines by months.
The Center for Veterinary Medicine processes over 400 new animal drug submissions annually. Each incomplete Form 0356V triggers an information request that consumes approximately 30 days of review time, directly impacting your market entry date and competitive position.
What you’ll learn:
📋 Exact submission scenarios requiring Form 0356V versus electronic alternatives, with decision trees for every application type
🔍 Line-by-line form completion guidance covering all 28 data fields, including common pitfalls that trigger FDA information requests
⚠️ Critical certification requirements distinguishing NADAs, ANADAs, and conditional approvals under current federal statutes
💰 User fee implications when Form 0356V accompanies your submission versus standalone fee cover sheets
🚫 Top 10 mistakes causing administrative delays, with real-world consequences and remediation strategies
Understanding FDA Form 0356V: The Veterinary Drug Application Cover Document
Form 0356V operates as the official cover document for new animal drug submissions to FDA’s Center for Veterinary Medicine. The form serves three distinct regulatory functions that directly impact processing time.
First, it provides the legal certification required under section 512(b)(1) of the Federal Food, Drug, and Cosmetic Act. This certification states you take responsibility for product compliance with federal standards. Second, it supplies the administrative routing information FDA uses to assign your submission to the correct review division within 72 hours of receipt. Third, it creates the permanent record linking all subsequent amendments, supplements, and correspondence to your base application number.
The form distinguishes between human drug applications using Form FDA 356h and veterinary applications. This separation exists because veterinary products face different regulatory pathways, user fee structures, and approval timelines than human pharmaceuticals.
When Form 0356V Is Mandatory
You must include Form 0356V with paper submissions falling under these categories. Original New Animal Drug Applications require the form whether you submit a complete NADA or phased technical sections supporting future approval. Abbreviated New Animal Drug Applications demand Form 0356V for both generic drug submissions and petitioned ANADAs with variations from the reference listed drug.
Applications for conditional approval under section 571(a)(2) require the form even though these applications do not contain full effectiveness data. Supplements requiring review of safety or effectiveness data need Form 0356V attached to each submission. Minor Changes and Stability Reports submitted as “B” submission types must include the completed form.
Master file submissions to FDA, whether Public Master Files or Veterinary Master Files, require Form 0356V for initial “A” submissions and “C” supplement submissions. Investigational file submissions supporting technical sections need the form when you submit data packages classified as “P” submission types or minor technical section submissions marked “M.”
Final printed labeling submissions classified as “G” submission types require Form 0356V when submitted separately from the approved application but before marketing begins. Reactivation submissions marked “E” and “R” types that restart review of previously incomplete applications need the form to restart the administrative clock.
When Form 0356V Is Not Required
Electronic submissions through eSubmitter do not require Form 0356V. The electronic submission tool captures the same certification and routing information through digital fields, eliminating form redundancy. This represents a critical efficiency gain, as electronic submissions reduce administrative processing time from 5 days to approximately 24 hours.
Protocol submissions marked “E” submission type do not need Form 0356V because these documents request FDA feedback rather than support application approval. Notices of claimed investigational exemption classified as “B” types operate outside the approval pathway and skip form requirements.
Requests for food-use authorization marked “O” submission types follow separate regulatory procedures that do not require Form 0356V. General correspondence not directly supporting application approval avoids form requirements, including routine status inquiries and meeting requests.
Critical Distinction: Form 0356V vs Form 356h
Understanding which form applies to your product prevents costly submission errors. Form 0356V applies exclusively to veterinary products regulated by the Center for Veterinary Medicine. These include drugs, devices, and biologics intended for animal use, whether livestock, companion animals, or aquaculture species.
Form FDA 356h applies to human drugs regulated by the Center for Drug Evaluation and Research or biologics regulated by the Center for Biologics Evaluation and Research. This form covers New Drug Applications, Abbreviated New Drug Applications, and Biologics License Applications for human pharmaceutical products.
The forms contain different data fields reflecting distinct regulatory requirements. Form 0356V includes sections specific to veterinary medicine, such as target animal species, veterinary feed directive information, and animal food safety data. Form 356h contains human-specific fields covering clinical trial data presentations, patient population descriptions, and prescription-to-over-the-counter switch information.
| Form Type | Regulatory Center | Product Category | Key Differentiator |
|---|---|---|---|
| 0356V | Center for Veterinary Medicine | New animal drugs | Target species field required |
| 356h | CDER or CBER | Human drugs/biologics | Clinical data presentation format |
Submitting the wrong form triggers an immediate incomplete notification from FDA. This adds 30 to 45 days to your review timeline while you correct and resubmit with proper documentation.
Complete Form 0356V Field-by-Field Requirements
Form 0356V contains 28 data fields organized into six major sections. Each field serves a specific regulatory or administrative function that impacts how FDA processes your submission.
Section 1: Application Information
Application or Investigational File Number: Enter your FDA-assigned number if one exists. For new submissions without prior FDA contact, leave this blank until FDA assigns a number upon receipt. The format follows either NADA followed by six digits, ANADA followed by six digits, or INAD followed by six digits for investigational files.
Date of Submission: Use the date your submission physically leaves your facility or the electronic transmission date for couriered materials. This date establishes the official filing clock for user fee purposes and regulatory review timelines. FDA counts calendar days from this date, not business days.
Section 2: Applicant Information
Applicant Name: Provide the legal business entity name exactly as registered with your state or country of incorporation. This name must match your Drug Establishment Registration exactly. Inconsistencies between Form 0356V and your establishment registration trigger information requests that delay processing.
Applicant Address: Include complete street address with building numbers where physical inspection can occur. FDA field investigators use this address for preapproval inspections and compliance follow-up. Post office boxes are not acceptable as the primary address because inspectors cannot access these locations.
Telephone and Facsimile Numbers: Include country codes for international applicants. FDA uses these contact methods for time-sensitive questions during the 60-day filing review period. Provide numbers monitored during U.S. Eastern business hours to avoid communication delays.
Contact Name: Designate your authorized representative or U.S. agent who holds signatory authority for your company. For applicants without U.S. presence, federal regulations under 21 CFR 514.1 require a U.S. agent with a physical U.S. address. This person receives all FDA correspondence and must possess authority to bind your company to regulatory commitments.
Section 3: Product Information
Proprietary Name: Enter your proposed brand name if one exists. For generic applications, this field may remain blank if you market under the established name only. Proprietary names require separate FDA proprietary name review to avoid medication errors and consumer confusion.
Established Name: Use the official name as listed in the U.S. Pharmacopeia, National Formulary, or official compendia. For new molecular entities without official names, provide the chemical name following International Union of Pure and Applied Chemistry nomenclature standards.
Dosage Form: Select from FDA’s standardized list including tablets, capsules, injectable solutions, topical ointments, oral suspensions, and medicated feeds. Your selection determines which stability testing requirements apply under 21 CFR 514.1(b)(8).
Strength: Express active ingredient concentration using metric units. For combination products, list all active ingredients with individual strengths. FDA requires consistency between strength on Form 0356V, your proposed labeling, and analytical methods in Module 3.
Route of Administration: Specify oral, topical, injectable (subcutaneous, intramuscular, intravenous), or other routes. This field determines which safety studies FDA requires and which review division receives assignment.
Section 4: Type of Submission
This section contains 15 checkboxes covering every submission category FDA accepts. You must check exactly one box that most accurately describes your submission type. Checking multiple boxes or leaving all unchecked triggers an information request.
Submission of Data to Investigational File: Select when providing study data supporting future NADA submission but not requesting approval yet. These phased submissions allow FDA feedback before committing to full application costs.
Original Application: Check for first-time NADA, ANADA, or conditional approval application. This triggers the full user fee assessment and standard review clock of 180 days under the Animal Drug User Fee Act.
Supplement Requiring Safety or Effectiveness Review: Use when proposing changes to approved applications that add new species, new indications, or significant manufacturing changes affecting product performance. These supplements carry the same review intensity as original applications.
Prior Approval, CBE, or CBE-30 Supplement: These three categories distinguish manufacturing and labeling changes by risk level. Prior approval supplements require FDA approval before implementing changes. Changes Being Effected allow immediate implementation upon FDA receipt. CBE-30 supplements permit implementation 30 days after FDA receipt unless FDA objects.
Minor Changes and Stability Report: Select for routine manufacturing refinements and annual stability data updates that do not affect product safety or effectiveness profiles.
Amendment to Pending Application: Use when providing additional information responding to FDA questions about submissions under active review. These do not restart review clocks but may extend goal dates if substantial new data requires evaluation.
Section 5: Submission Content Checklist
This section lists all technical components that may appear in veterinary drug applications. You must check every box describing information types included in your current submission. This section operates as a table of contents validation tool.
For NADA submissions, you check boxes 1 through 8 covering identification, table of contents, labeling, chemistry manufacturing and controls, human food safety, target animal safety, effectiveness, environmental impact, freedom of information summary, samples (if requested), veterinary feed directive copies, required commitments, and patent information.
For ANADA submissions, you check boxes 9 through 11 covering bioequivalence documentation, suitability petitions if applicable, abbreviated technical sections, and copies of approved drug labeling.
The “Other” category captures unique submission types not fitting standard classifications. When checking “Other,” you must provide detailed written explanation in your cover letter describing exactly what the submission contains and which regulatory requirement it satisfies.
Section 6: Certification and Signature
The signature block requires an authorized official signature, printed name, title, and date. This signature certifies under penalty of law that all information in your submission is true, accurate, and complete to the best of your knowledge.
For U.S.-based applicants, the company officer or designated representative signs. For foreign applicants without U.S. operations, both your company representative and your designated U.S. agent must sign Form 0356V. This dual signature requirement under 21 CFR 514.1 ensures FDA can enforce compliance actions against a party subject to U.S. jurisdiction.
Electronic signatures are not acceptable on paper Form 0356V submissions. You must provide original ink signatures in blue or black ink. Stamped signatures, signature labels, or photocopied signatures invalidate the form and trigger immediate return without filing.
Three Most Common Form 0356V Scenarios
Understanding real-world application scenarios clarifies when Form 0356V requirements apply and how completion differs by situation.
Scenario 1: New Generic Antibiotic for Livestock
A pharmaceutical manufacturer develops a generic oxytetracycline injection for cattle, identical to an approved reference drug. The company must submit an Abbreviated New Animal Drug Application demonstrating bioequivalence to the pioneer product.
| Submission Requirement | Form 0356V Completion |
|---|---|
| Application type checkbox | Check “Original Application” and “ANADA” |
| Bioequivalence data | Check box 9(b) under Submission Content |
| Reference drug identification | Provide name and ANADA number in cover letter |
| Chemistry data | Check box 9(d) for abbreviated CMC section |
| Labeling | Check box 9(c) and specify draft facsimile labeling |
The manufacturer submits three identical copies with Form 0356V placed before the cover letter and table of contents in each copy. FDA assigns an ANADA number within 5 business days and begins the 180-day review clock.
If the manufacturer submits electronically through eSubmitter instead, Form 0356V is not required. The electronic tool captures the same information through digital fields, and FDA’s system auto-generates the ANADA number instantly upon successful upload.
Scenario 2: Supplement Adding New Species Indication
A company holds an approved NADA for a pain medication approved only for dogs. The company now seeks approval to add cats as a target species based on new safety and effectiveness studies.
This represents a major change requiring a supplement with safety and effectiveness review. The company checks the “Supplement Requiring Review of Safety or Effectiveness Data” box on Form 0356V.
| Action Required | Regulatory Consequence |
|---|---|
| Submit new cat safety studies | FDA conducts full target animal safety review |
| Submit new cat effectiveness studies | FDA applies substantial evidence standard |
| Propose revised labeling adding cats | FDA reviews for accurate species-specific information |
| Pay supplement user fee | Fee equals 50% of original NADA fee |
| Wait for FDA approval | Cannot market for cats until approval letter received |
The supplement remains pending until FDA issues an approval letter. Marketing the product for cats before approval constitutes illegal distribution of an unapproved new animal drug under section 512(a) of the Federal Food, Drug, and Cosmetic Act, carrying civil penalties up to $250,000 per violation.
Scenario 3: Conditional Approval for Unmet Animal Need
A biotechnology company develops a novel vaccine for a serious chicken disease affecting egg production. The disease lacks approved treatments, qualifying for conditional approval under section 571 of the Federal Food, Drug, and Cosmetic Act.
Conditional approval allows marketing before completing full effectiveness studies, provided the company demonstrates reasonable expectation of effectiveness and meets safety standards. Form 0356V requires specific checkboxes unique to this pathway.
| Conditional Approval Requirement | Form 0356V Documentation |
|---|---|
| Check “Application for Conditional Approval” | Distinguishes from full NADA pathway |
| Submit target animal safety data | Check box 3(d) under technical sections |
| Submit reasonable expectation of effectiveness | Check box 3(e) second option |
| Commit to complete effectiveness studies | Check box 6(a) for post-approval commitments |
| Submit annual progress reports | Automatic requirement for conditional approval status |
The conditional approval lasts a maximum of five years. During this period, the company must complete field effectiveness studies and convert to full NADA approval. Failure to meet milestones results in automatic conditional approval termination and mandatory market withdrawal.
User Fee Cover Sheet Requirements With Form 0356V
The Animal Drug User Fee Act mandates fees for most new animal drug submissions. These fees fund FDA’s review activities and facility inspection programs under the statute.
When submitting paper applications requiring Form 0356V, you must also include Form FDA 3546, the Animal Drug User Fee Cover Sheet. This second form accompanies but does not replace Form 0356V. Both forms serve distinct functions in the administrative processing chain.
Form FDA 3546 captures payment identification numbers linking your fee payment to your application. FDA cannot begin substantive review until it confirms fee payment and matches the payment to your submission through the cover sheet cross-reference system.
For fiscal year 2026, ADUFA fees are: original NADA requiring clinical data costs $513,200; original ANADA costs $258,800; supplements requiring clinical data review cost $256,600; establishment fees run $107,500 annually; and product fees total $31,200 per product annually.
You submit fee payment before or simultaneously with your application. Payment occurs through the FDA payment portal, wire transfer, or check. The payment system generates a unique payment identification number beginning with “AD” for animal drugs. You enter this number on Form FDA 3546 to create the cross-reference.
| Payment Timing | Processing Impact |
|---|---|
| Payment submitted 5+ days before application | FDA begins review immediately upon application receipt |
| Payment submitted same day as application | FDA holds application in administrative processing 3-5 days pending payment confirmation |
| Payment submitted after application | FDA issues incomplete letter after 5 business days, review clock does not start |
If you submit electronically through eSubmitter, the system prompts for payment identification number during upload. The electronic workflow automatically links payment to submission, eliminating manual cross-referencing delays.
Certain applicants qualify for user fee waivers including small businesses submitting their first animal drug application and applicants developing products for minor species or minor uses where market size cannot support development costs. Waiver requests require separate submission with financial documentation supporting the request basis.
Electronic Submission Alternative: When to Skip Form 0356V
The FDA eSubmitter tool provides an electronic alternative to paper submissions requiring Form 0356V. This web-based portal captures the same certification and routing information through digital entry fields, making the paper form redundant.
When you submit through eSubmitter, you complete an electronic application profile answering the same questions appearing on paper Form 0356V. The system generates a submission summary report replacing the paper form. This report accompanies your electronic files and provides FDA reviewers with identical information.
Electronic submission offers significant advantages over paper filing. Processing time drops from 5 business days to approximately 24 hours. FDA’s automated systems immediately route electronic submissions to the correct review division based on your profile selections. Electronic submissions eliminate common paper-form errors including missing signatures, illegible handwriting, and checkbox ambiguities.
The eSubmitter portal includes built-in validation checks preventing submission of incomplete applications. If you skip required fields or select contradictory options, the system flags errors before you finalize transmission. This front-end validation eliminates most information requests that plague paper submissions.
However, electronic submission requires technical preparation including installing FDA’s submission software, obtaining digital certificates, and formatting your documents according to eCTD specifications for veterinary products. For applicants submitting a single application, paper submission with Form 0356V may prove more efficient than investing in electronic infrastructure setup.
For companies with ongoing development programs submitting multiple applications and amendments, electronic submission becomes cost-effective after the second or third submission. The time savings and error reduction quickly offset initial setup costs.
Do’s and Don’ts for Form 0356V Completion
Following best practices prevents the most common completion errors that trigger FDA information requests and processing delays.
Do’s
Do verify your FDA establishment registration status before completing Form 0356V. Your applicant name on the form must match your establishment registration exactly. FDA’s cross-reference system flags mismatches within 72 hours, generating an information request. Log into FDA’s Unified Registration and Listing System to confirm your registered legal entity name before form completion.
Do designate a U.S. agent with genuine authority if you operate outside the United States. Federal regulations require foreign applicants to identify a U.S. agent with a physical U.S. address who can accept legal service of process. This person must hold actual authority to represent your company in regulatory matters, not merely serve as a mail drop. FDA may contact your U.S. agent directly regarding compliance issues.
Do include Form 0356V before your cover letter in the submission package. FDA’s administrative staff processes submissions in document order. Placing Form 0356V on top ensures immediate routing to the correct division. When the form appears later in the package, administrative staff may miss it, causing misrouting and review delays of 10 to 15 business days.
Do use the current version of Form 0356V downloaded from FDA’s website. The form undergoes periodic updates reflecting regulatory changes. Using an outdated form version with different checkbox options or obsolete field labels triggers an information request. Check the form footer for the revision date and verify it matches the current version posted on the FDA forms page.
Do provide complete contact information including international dialing codes for telephone and fax numbers. FDA reviewers often have urgent technical questions requiring rapid response during the 60-day filing review period. Incomplete contact information prevents timely communication and may result in incomplete findings that extend review timelines.
Don’ts
Don’t check multiple boxes in the Type of Submission section. This section requires selection of exactly one submission type. Checking multiple boxes creates ambiguity about which review pathway and user fee applies to your submission. FDA’s system cannot process applications with multiple submission types checked, triggering an immediate information request and processing halt.
Don’t use electronic signatures, stamps, or photocopied signatures on paper Form 0356V. Federal regulations require original handwritten signatures in ink for paper submissions. Electronic signatures lack the legal authentication required for paper document certification. Stamped or photocopied signatures cannot verify the signatory’s identity at the time of signing. FDA returns improperly signed forms without filing.
Don’t submit Form 0356V with electronic submissions through eSubmitter. Including the paper form with electronic submissions creates redundant information that confuses FDA’s automated processing systems. The eSubmitter portal captures all Form 0356V information through digital fields, making the paper form unnecessary. Redundant submissions may trigger validation errors or system processing failures.
Don’t leave the Submission Content checklist section blank. You must check every box describing content types included in your submission. Leaving this section blank forces FDA reviewers to manually inventory your submission contents, adding 3 to 5 business days to administrative processing time. FDA may issue an information request asking you to specify which content types your submission includes.
Don’t assume your U.S. address automatically satisfies foreign applicant requirements. If your company is incorporated outside the United States, you must designate a U.S. agent even if you maintain a U.S. office. The U.S. agent requirement stems from legal jurisdiction for enforcement actions. Your U.S. office location does not automatically satisfy this requirement unless you formally designate an officer at that location as your U.S. agent on Form 0356V.
Mistakes to Avoid When Completing Form 0356V
These ten errors appear most frequently in FDA processing deficiency reports and information requests sent to applicants.
Mistake 1: Inconsistent applicant names between Form 0356V and establishment registration. FDA’s automated cross-reference system matches the applicant name on Form 0356V against your Drug Establishment Registration. Name variations like abbreviations, omitted middle terms, or different legal entity structures trigger system flags. For example, submitting as “ABC Veterinary Inc.” when registered as “ABC Veterinary Products Incorporated” creates a mismatch requiring manual resolution.
Mistake 2: Missing signature from U.S. agent for foreign applicants. Foreign applicants must obtain signatures from both their company representative and their designated U.S. agent. Submissions with only the foreign company signature lack proper legal certification under 21 CFR 514.1. FDA returns these submissions without filing until both signatures appear.
Mistake 3: Checking wrong application type for supplements. Many applicants incorrectly check “Original Application” when submitting supplements to already-approved NADAs. Supplements require checking the specific supplement type matching the proposed change category. Misclassified supplements receive incorrect user fee assessments and wrong review division assignments, causing 30 to 60-day processing delays.
Mistake 4: Omitting establishment registration numbers. While Form 0356V does not explicitly request establishment registration numbers, FDA guidance recommends including these numbers in the applicant information section or cover letter. Missing registration numbers require FDA staff to manually search establishment databases, adding processing time and increasing misfiling risk.
Mistake 5: Incomplete product strength information for combination products. Products containing multiple active ingredients require listing each ingredient with its individual strength. Listing only total combined strength or omitting secondary ingredients creates ambiguity about product composition. FDA cannot process applications without clear active ingredient identification.
Mistake 6: Using post office boxes as primary applicant address. FDA field investigators conduct preapproval inspections at manufacturing and testing facilities. Post office boxes provide no physical location for inspections. Applications listing P.O. boxes as the sole address receive information requests demanding physical facility addresses where inspections can occur.
Mistake 7: Selecting “Other” submission type without detailed explanation. The “Other” checkbox serves as a catch-all for unusual submission types not fitting standard categories. However, selecting “Other” without providing specific written explanation in your cover letter creates administrative uncertainty. FDA cannot route the submission to the appropriate review division without understanding the submission nature.
Mistake 8: Failing to update Form 0356V in amendments to pending applications. When submitting amendments to applications under review, you must include an updated Form 0356V with each amendment. The updated form should check “Amendment to Pending Application” and reference the original application number. Amendments lacking Form 0356V may become separated from the parent application in FDA’s document management system.
Mistake 9: Inconsistent information between Form 0356V and cover letter. Your cover letter should align with Form 0356V regarding submission type, content description, and proposed changes. Contradictions between these documents create confusion about your actual request. For example, if Form 0356V indicates a supplement but your cover letter describes an original application, FDA must issue an information request to clarify your true intent.
Mistake 10: Submitting outdated form versions lacking current revision date. FDA updates Form 0356V periodically to reflect regulatory changes, new submission types, and revised procedural requirements. Using an outdated form version may lack checkboxes for newer submission categories or contain obsolete terminology. Always download the current form version immediately before finalizing your submission package to ensure you use the latest revision.
Comparing Submission Types Requiring Form 0356V
Different veterinary drug submission types carry distinct Form 0356V completion requirements and FDA processing procedures.
NADA vs ANADA vs Conditional Approval
| Application Type | Data Requirements | Review Timeline | User Fee | Form 0356V Key Differences |
|---|---|---|---|---|
| New Animal Drug Application (NADA) | Full safety and effectiveness data | 180 days standard | $513,200 (FY 2026) | Check boxes 1-8 for complete technical sections |
| Abbreviated NADA (ANADA) | Bioequivalence to reference drug | 180 days standard | $258,800 (FY 2026) | Check boxes 9-11 for abbreviated sections, list reference drug |
| Conditional Approval | Safety plus reasonable expectation of effectiveness | 180 days initial, 5-year completion requirement | $513,200 (FY 2026) | Check conditional approval box, commit to post-approval studies |
The key distinction appears in the Submission Content checklist section. NADA applications check boxes covering full technical sections including extensive target animal safety studies, substantial evidence of effectiveness, and comprehensive chemistry manufacturing and controls data.
ANADA applications check abbreviated section boxes and must provide the reference drug name and approved ANADA number. The application relies on FDA’s previous approval of the reference drug for safety and effectiveness findings, requiring only bioequivalence demonstration.
Conditional approval applications check boxes for safety data and reasonable expectation of effectiveness rather than substantial evidence. The form must also indicate the post-approval study commitments required to convert conditional approval to full NADA approval within five years.
Original Applications vs Supplements vs Amendments
These three submission categories represent different stages in the product approval lifecycle and require distinct Form 0356V checkbox selections.
Original applications initiate the approval process for products never before reviewed by FDA. These applications check “Original Application” and specify whether submitting a NADA, ANADA, or conditional approval request. Original applications trigger full user fee assessment and standard 180-day review clocks.
Supplements propose changes to already-approved applications. These fall into five categories by change significance. Prior approval supplements require FDA approval before implementing major changes affecting product safety or effectiveness. CBE-30 supplements allow implementation 30 days after submission for moderate changes. CBE supplements permit immediate implementation upon submission for minor changes.
Chemistry, manufacturing, and control supplements focus on manufacturing process changes, specification revisions, or facility additions without affecting labeled indications or target species. Labeling supplements modify product labeling for new information, dosage clarifications, or safety updates.
Amendments provide additional information about pending applications or supplements under active FDA review. Amendments do not initiate new review processes but respond to FDA questions or deficiency letters. Form 0356V for amendments must check “Amendment to Pending Application” and clearly reference the application number and submission date of the pending application being amended.
| Submission Category | Triggers New Review Clock | Requires User Fee | Form 0356V Checkbox |
|---|---|---|---|
| Original Application | Yes – 180 days | Yes – full amount | “Original Application” |
| Prior Approval Supplement | Yes – 180 days | Yes – 50% of original | “Supplement Requiring Safety/Effectiveness Review” |
| CBE-30 Supplement | Yes – 180 days | No | “Chemistry, Manufacturing, and Controls Supplement” or “Labeling Supplement” |
| CBE Supplement | Yes – 180 days | No | Same as CBE-30 |
| Amendment | No – extends parent review | No | “Amendment to Pending Application” |
Misclassifying your submission type causes cascading problems including wrong user fee assessment, incorrect review division assignment, and inappropriate application of review standards. FDA reviewers encountering misclassified submissions must halt review and issue information requests for correct classification, adding 30 to 45 days to the approval timeline.
Pros and Cons of Paper Form 0356V vs Electronic Submission
Understanding the tradeoffs between submission methods helps you select the approach matching your organizational capabilities and submission frequency.
Paper Submission with Form 0356V
Pro: No specialized software or technical infrastructure required. You complete Form 0356V using standard PDF software and assemble your submission using office printing and binding equipment. This eliminates the need for eCTD formatting software, digital certificate management, and IT support for electronic transmission troubleshooting.
Pro: Suitable for one-time or infrequent submitters. Small companies or academic institutions submitting a single animal drug application avoid the learning curve and setup costs associated with electronic submission platforms. The time investment to master paper submission procedures proves more efficient than learning electronic systems for single-use scenarios.
Pro: Physical document control and verification. You can visually inspect each page of your submission package before mailing, verifying presence of all required documents, proper pagination, and correct document order. This tangible verification reduces submission errors for organizations lacking sophisticated document management systems.
Pro: No electronic transmission failures or gateway timeout issues. Paper submissions avoid technical problems including file upload failures, gateway connection timeouts, file size limit complications, and digital certificate expiration issues that can prevent successful electronic submission at critical moments.
Pro: Clear separation between administrative forms and technical content. Form 0356V sits physically atop your submission package, providing obvious identification and routing information to FDA mailroom staff. Electronic submissions intermingle administrative data with technical content in the same electronic structure, occasionally causing processing confusion.
Con: Significantly longer processing time of 5 to 10 business days. FDA’s administrative staff must manually log paper submissions into tracking systems, physically route packages to review divisions, and scan key documents for electronic recordkeeping. Electronic submissions bypass these manual steps through automated processing.
Con: Higher risk of missing or illegible information. Handwritten entries on Form 0356V may be illegible, signatures may be unclear, and checkbox marks may be ambiguous. FDA staff encountering illegible information must contact applicants for clarification, causing processing delays.
Con: No built-in validation to catch completion errors. Paper forms lack the automatic error-checking that electronic systems provide. You can submit Form 0356V with contradictory checkboxes marked, required fields left blank, or illogical combinations that electronic systems would reject before transmission.
Con: Requires physical document duplication and shipment. FDA regulations require three identical copies of paper submissions. Creating, verifying, and shipping three complete submission packages increases preparation time, costs, and environmental impact compared to single electronic file upload.
Con: Vulnerable to shipping delays and delivery failures. Courier delays, misdirected packages, weather disruptions, and package damage during transit can prevent timely FDA receipt. Electronic submissions transmit instantly and generate immediate receipt confirmations eliminating shipping uncertainty.
Electronic Submission via eSubmitter
Pro: Drastically reduced processing time to 24 hours. FDA’s automated systems immediately log electronic submissions, assign application numbers, route to review divisions, and notify reviewers of new arrivals. This automation eliminates manual administrative steps consuming 5 to 10 business days for paper submissions.
Pro: Built-in validation preventing common errors. The eSubmitter portal includes field-level validation checking for required information completeness, proper format compliance, and logical consistency. The system rejects submissions with missing required fields or contradictory selections, preventing errors before transmission rather than discovering them during FDA processing.
Pro: Instant transmission confirmation and receipt acknowledgment. Upon successful upload, eSubmitter generates immediate transmission reports confirming FDA receipt. You receive electronic confirmation within minutes rather than waiting days for courier delivery confirmation and additional days for FDA mailroom processing.
Pro: Eliminates physical document production and shipping costs. Electronic submission removes expenses for printing hundreds or thousands of pages in triplicate, binding three copies, packaging for shipment, and paying courier fees. For large submissions exceeding 1,000 pages, savings can reach several thousand dollars per submission.
Pro: Better environmental sustainability profile. Avoiding paper consumption, printer toner use, binding materials, and shipping fuel consumption aligns with corporate sustainability commitments and reduces environmental impact.
Con: Requires significant upfront investment in electronic infrastructure. Implementing electronic submission capability demands eCTD software licenses costing $10,000 to $50,000 annually, IT staff training consuming weeks or months, and obtaining and managing FDA digital certificates. Small organizations submitting infrequently may find these costs exceed paper submission expenses.
Con: Steep learning curve for first-time electronic submitters. Mastering eCTD document structure, proper file naming conventions, metadata creation, validation tools, and submission portal navigation requires substantial time investment. First electronic submissions typically take 3 to 4 times longer to prepare than subsequent submissions once familiarity develops.
Con: Technical failures can prevent time-sensitive submissions. Electronic submission gateway outages, file validation errors discovered at transmission time, digital certificate expiration, and file size limit exceedances can prevent successful submission when deadlines approach. Paper submission avoids these technical pitfalls through physical package shipment.
Con: Less intuitive separation of administrative and technical information. Electronic submissions integrate administrative metadata with technical documents in unified electronic structures. This integration occasionally causes confusion about where specific administrative information resides within the submission package compared to obvious physical placement of Form 0356V atop paper packages.
Con: Requires maintenance of electronic submission infrastructure. Digital certificates expire annually requiring renewal, eCTD software requires regular updates for regulatory changes, and staff turnover necessitates ongoing training programs. Paper submission skills remain stable over time without system maintenance requirements.
Detailed Process for Major Changes Requiring Prior Approval Supplements
Prior approval supplements represent the highest-risk category of changes to approved animal drugs. These changes require FDA review and approval before implementation because they may affect product safety or effectiveness.
Changes requiring prior approval supplements include adding new target species beyond originally approved species, adding new indications or claims beyond original approval scope, changing active ingredient manufacturing sources or synthetic routes, and implementing major manufacturing process changes affecting product characteristics.
Additional prior approval triggers include establishing new manufacturing facilities for active ingredients or finished products, widening specification ranges for critical quality attributes, and changing drug product formulation by adding, deleting, or altering inactive ingredients.
When preparing a prior approval supplement, you complete Form 0356V checking “Supplement Requiring Review of Safety or Effectiveness Data.” You must clearly describe the proposed change in your cover letter with specific details enabling FDA to understand the change scope and rationale.
The supplement must include all data supporting the proposed change. For new species additions, this includes target animal safety studies in the new species demonstrating adequate safety margin, effectiveness studies providing substantial evidence in the new species, and pharmacokinetics data in the new species supporting dosage recommendations.
For manufacturing changes, you provide validation data demonstrating the changed process produces product meeting all specifications, comparative analytical data showing equivalence between old and new manufacturing processes, and stability data confirming the change does not adversely affect product shelf life.
| Change Type | Required Supporting Data | Typical Review Time | Implementation Timing |
|---|---|---|---|
| New target species | Safety studies, effectiveness studies, pharmacokinetics in new species | 180 days | After FDA approval letter received |
| New indication for approved species | Effectiveness studies supporting new claim | 180 days | After FDA approval letter received |
| Major manufacturing change | Process validation, comparative analytics, stability data | 180 days | After FDA approval letter received |
| New manufacturing facility | Facility qualification, process validation, stability studies | 180 days plus inspection time | After FDA approval and facility inspection clearance |
FDA assigns prior approval supplements to review divisions within 72 hours of receipt. Reviewers conduct comprehensive evaluation applying the same scientific standards used for original applications. If deficiencies exist, FDA issues a complete response letter describing deficiencies and requesting additional information.
You cannot implement prior approval supplement changes until receiving FDA’s approval letter. Implementing changes before approval violates federal regulations and subjects your product to regulatory action as an unapproved new animal drug. FDA may issue warning letters, impose civil penalties up to $250,000 per violation, or initiate seizure proceedings for products manufactured under unapproved changes.
Special Considerations for Foreign Applicants
Foreign applicants face additional requirements beyond domestic applicants when completing Form 0356V and submitting veterinary drug applications.
Federal regulations under 21 CFR 514.1 require foreign applicants to designate a U.S. agent. This agent must be an individual or entity with a physical presence in the United States who agrees to represent the foreign applicant in regulatory matters. The U.S. agent serves as the official point of contact for all FDA communications and can accept legal service of process on behalf of the foreign company.
The U.S. agent designation must appear clearly on Form 0356V in the Contact Name section. The form must indicate the agent’s U.S. physical address, U.S. telephone number, and authority to act on the applicant’s behalf. Both the foreign applicant’s authorized representative and the U.S. agent must sign Form 0356V, providing dual signatures certifying submission completeness.
Foreign manufacturing facilities require FDA inspection before application approval. You must indicate all foreign manufacturing facility locations on Form 0356V and in your manufacturing section technical documentation. FDA coordinates foreign facility inspections through its Office of Regulatory Affairs field offices and international partners.
Foreign facility inspections typically add 60 to 90 days to approval timelines compared to domestic facilities. This additional time accounts for international travel coordination, potential language interpretation needs, and extended document review periods for records maintained in foreign languages.
All submission documents must be in English or accompanied by certified English translations. Form 0356V itself must be completed in English. If your source documents exist in foreign languages, you must provide certified translations and submit both the original language version and English translation to FDA.
Time zone differences affect communication efficiency between foreign applicants and FDA reviewers. FDA operates on U.S. Eastern Time for all official communications. Foreign applicants should designate representatives available during U.S. business hours to ensure timely responses to FDA questions during critical review periods.
International applicants must use the same user fee payment mechanisms as domestic applicants. This requires establishing U.S. dollar payment capability through wire transfer, electronic payment portal, or check drawn on U.S. financial institutions. User fees cannot be paid in foreign currencies or through foreign banking systems.
FAQs
Is Form 0356V required for electronic submissions through eSubmitter?
No. The eSubmitter electronic portal captures all Form 0356V information through digital entry fields, making the paper form redundant and unnecessary for electronic submissions.
Can I use Form 356h instead of Form 0356V for veterinary drugs?
No. Form 356h applies exclusively to human drugs and biologics regulated by CDER or CBER, while Form 0356V applies only to veterinary products regulated by CVM.
Must foreign applicants provide both signatures on Form 0356V?
Yes. Federal regulations require both the foreign company representative’s signature and the designated U.S. agent’s signature to satisfy certification requirements for foreign applicants under 21 CFR 514.1.
Does every supplement to an approved NADA require Form 0356V?
Yes. All paper supplements including prior approval, CBE-30, CBE, and labeling supplements require Form 0356V unless you submit electronically through eSubmitter.
Can I submit Form 0356V with electronic signature?
No. Paper Form 0356V requires original handwritten signatures in ink. Electronic signatures are acceptable only for electronic submissions through the eSubmitter portal.
Is Form 0356V required for investigational protocols?
No. Protocol submissions classified as “E” submission types do not support application approval and therefore do not require Form 0356V.
How long does FDA take to process Form 0356V?
Paper submissions with Form 0356V take 5 to 10 business days for administrative processing; electronic submissions process within 24 hours without requiring the paper form.
Can I check multiple boxes in the Type of Submission section?
No. You must check exactly one box that most accurately describes your submission type to enable proper routing and user fee assessment.
Does Form 0356V satisfy the user fee payment requirement?
No. Form 0356V certifies submission content but Form FDA 3546 handles user fee payment identification and must accompany Form 0356V for fee-required submissions.
Must I include Form 0356V in amendments to pending applications?
Yes. Each amendment requires an updated Form 0356V checking “Amendment to Pending Application” and referencing the parent application number for proper filing.
Can I submit Form 0356V as a scanned PDF file?
No. Electronic submissions use the eSubmitter portal which captures Form 0356V information digitally; scanned PDF versions of the paper form are not acceptable.
Is Form 0356V required for annual reports?
No. Annual reports for approved NADAs follow different submission procedures and do not require Form 0356V unless specific technical sections warrant supplement submission.
Does incomplete Form 0356V stop the FDA review clock?
Yes. FDA issues an incomplete notification within 5 business days of discovering Form 0356V deficiencies, and the review clock does not start until deficiencies are corrected.
Can my U.S. office substitute for the U.S. agent requirement?
No. Foreign-incorporated companies must formally designate a specific individual at their U.S. office as the U.S. agent with signatory authority on Form 0356V.
Is Form 0356V required for master file submissions?
Yes. Initial master file submissions classified as “A” types and master file supplements classified as “C” types require Form 0356V for paper submissions.